Press Release
Category Added in a WPeMatico Campaign
-
Bounteous Acquires Cartesian, Enhancing Deep Data and Analytics Capabilities to Accelerate Enterprise AI
Acquisition also strengthens telecommunications expertise and accelerates global growth FRISCO, Texas and LONDON, May 12, 2026 /PRNewswire/ — Bounteous, an…
Read More » -
AI Doesn’t Block Adult Content. It Blocks Adult Discovery.
New Everything-PR Study Finds That ChatGPT, Claude, Perplexity, and Google AI Overviews Surface Adult Brands When Named — and Route…
Read More » -
Pearson and Salesforce Expand Partnership to Accelerate Workforce AI Readiness
Pearson will provide role insights, identify skills gaps, and deliver targeted learning for Salesforce employees HOBOKEN, N.J., May 12, 2026…
Read More » -
Cizzle Bio CEO Bill Behnke Participates in National Oncology Commercialization Panel at City of Hope’s 25th Ci4CC Summit
SAN ANTONIO, May 12, 2026 /PRNewswire/ — Cizzle Bio, Inc., a biotechnology company advancing innovative biomarker blood tests for the early…
Read More » -
SwitchBot Officially Launches KATA Friends, AI Pets That Truly Grow With You
TOKYO, May 12, 2026 /PRNewswire/ — SwitchBot, a leading provider of AI-enabled embodied home robotics systems, today announced the launch…
Read More » -
FirstComm Announces Mike Bee as Vice President of Sales
Industry veteran brings more than two decades of telecommunications experience and a proven track record of revenue growth AKRON, Ohio,…
Read More » -
Aqua Membranes Named Semifinalist in $119 Million XPRIZE Water Scarcity Competition
The company’s patented Printed Spacer Technology® advances in global race to revolutionize seawater desalination. ALBUQUERQUE, N.M., May 12, 2026 /PRNewswire/…
Read More » -
AI EVERYTHING KENYA X GITEX KENYA to anchor new era of inclusive AI and digital sovereignty for East Africa
In partnership with the Office of the Special Envoy on Technology of the Republic of Kenya, East Africa’s largest AI…
Read More » -
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in…
Read More »